These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31037274)

  • 21. Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia.
    Strauss GP; Chapman HC; Keller WR; Koenig JI; Gold JM; Carpenter WT; Buchanan RW
    J Psychiatr Res; 2019 May; 112():38-43. PubMed ID: 30849617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.
    Woolley JD; Chuang B; Fussell C; Scherer S; Biagianti B; Fulford D; Mathalon DH; Vinogradov S
    Psychol Med; 2017 May; 47(7):1311-1322. PubMed ID: 28091349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation.
    Dwyer KR; Andrea AM; Savage CLG; Orth RD; Shan L; Strauss GP; Adams HA; Kelly DL; Weiner E; Gold JM; McMahon RP; Carpenter WT; Buchanan RW; Blanchard JJ
    Schizophr Bull Open; 2020 Jan; 1(1):sgaa001. PubMed ID: 32803156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.
    Caravaggio F; Gerretsen P; Mar W; Chung JK; Plitman E; Nakajima S; Kim J; Iwata Y; Patel R; Chakravarty MM; Remington G; Graff-Guerrero A; Menon M
    Psychoneuroendocrinology; 2017 Jul; 81():80-87. PubMed ID: 28431278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia.
    Jesso S; Morlog D; Ross S; Pell MD; Pasternak SH; Mitchell DG; Kertesz A; Finger EC
    Brain; 2011 Sep; 134(Pt 9):2493-501. PubMed ID: 21859765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unaltered Oxytocin and Vasopressin Plasma Levels in Patients with Schizophrenia After 4 Months of Daily Treatment with Intranasal Oxytocin.
    Busnelli M; Dagani J; de Girolamo G; Balestrieri M; Pini S; Saviotti FM; Scocco P; Sisti D; Rocchi M; Chini B
    J Neuroendocrinol; 2016 Apr; 28(4):. PubMed ID: 26715485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot Randomized, Double-Blind, Placebo-Controlled Crossover Trial Evaluating the Feasibility of an Intranasal Oxytocin in Improving Social Cognition in Individuals Living with Alzheimer's Disease.
    Michaelian JC; McCade D; Hoyos CM; Brodaty H; Harrison F; Henry JD; Guastella AJ; Naismith SL
    J Alzheimers Dis Rep; 2023; 7(1):715-729. PubMed ID: 37483320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.
    Feifel D; Macdonald K; Cobb P; Minassian A
    Schizophr Res; 2012 Aug; 139(1-3):207-10. PubMed ID: 22682705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials.
    Sabe M; Zhao N; Crippa A; Strauss GP; Kaiser S
    Int J Neuropsychopharmacol; 2021 Aug; 24(8):601-614. PubMed ID: 33890987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of adjunctive intranasal oxytocin in patients with schizophrenia.
    Ota M; Yoshida S; Nakata M; Yada T; Kunugi H
    Postgrad Med; 2018 Jan; 130(1):122-128. PubMed ID: 29105546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients.
    van Zuiden M; Frijling JL; Nawijn L; Koch SBJ; Goslings JC; Luitse JS; Biesheuvel TH; Honig A; Veltman DJ; Olff M
    Biol Psychiatry; 2017 Jun; 81(12):1030-1040. PubMed ID: 28087128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Null results of oxytocin and vasopressin administration across a range of social cognitive and behavioral paradigms: Evidence from a randomized controlled trial.
    Tabak BA; Teed AR; Castle E; Dutcher JM; Meyer ML; Bryan R; Irwin MR; Lieberman MD; Eisenberger NI
    Psychoneuroendocrinology; 2019 Sep; 107():124-132. PubMed ID: 31128568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial.
    Watanabe T; Abe O; Kuwabara H; Yahata N; Takano Y; Iwashiro N; Natsubori T; Aoki Y; Takao H; Kawakubo Y; Kamio Y; Kato N; Miyashita Y; Kasai K; Yamasue H
    JAMA Psychiatry; 2014 Feb; 71(2):166-75. PubMed ID: 24352377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.
    Bradley ER; Woolley JD
    Neurosci Biobehav Rev; 2017 Sep; 80():36-56. PubMed ID: 28506922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
    Kuppens RJ; Donze SH; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial.
    Guastella AJ; Gray KM; Rinehart NJ; Alvares GA; Tonge BJ; Hickie IB; Keating CM; Cacciotti-Saija C; Einfeld SL
    J Child Psychol Psychiatry; 2015 Apr; 56(4):444-52. PubMed ID: 25087908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin 4 receptor brain binding and oxytocin-promoted affective and social cognition in healthy women - A randomized controlled trial.
    Dam VH; Andersen SH; Pedersen ST; Stenbæk DS; Frokjaer VG
    Compr Psychoneuroendocrinol; 2024 Feb; 17():100224. PubMed ID: 38288372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Social motivation in schizophrenia: The impact of oxytocin on vigor in the context of social and nonsocial reinforcement.
    Fulford D; Treadway M; Woolley J
    J Abnorm Psychol; 2018 Jan; 127(1):116-128. PubMed ID: 29369669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task.
    Horta de Macedo LR; Zuardi AW; Machado-de-Sousa JP; Chagas MH; Hallak JE
    Psychiatry Res; 2014 Dec; 220(1-2):125-8. PubMed ID: 25190346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder.
    Guastella AJ; Howard AL; Dadds MR; Mitchell P; Carson DS
    Psychoneuroendocrinology; 2009 Jul; 34(6):917-23. PubMed ID: 19246160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.